This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
McKesson (MCK) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Walgreens (WBA) Expands Access to COVID-19 Test With LabCorp
by Zacks Equity Research
Walgreens (WBA) will enable more communities to access reliable, convenient testing services as and when required with the addition of Pixel by LabCorp COVID-19 at-home collection kit.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
PacBio (PACB) Supports SickKids With Sequencing Technology
by Zacks Equity Research
PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.
Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
McKesson (MCK) Up 4.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thermo Fisher (TMO) Extends Collaboration With Symphogen
by Zacks Equity Research
Thermo Fisher's (TMO) recent extension of collaboration with Symphogen is intended to support biopharmaceutical discovery and development.
Medtronic (MDT) Gains Market Share Despite COVID Headwinds
by Zacks Equity Research
In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quidel (QDEL) Rallies 17.4% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Quidel (QDEL) stock rallies on better-than-expected fourth-quarter performance and strong diagnostics portfolio.
Here's Why You Should Invest in AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment.
Insulet (PODD) Product Volume Up, COVID-Led Softness Persists
by Zacks Equity Research
Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.
Henry Schein (HSIC) Expands Data Analytics to Private Practices
by Zacks Equity Research
Henry Schein's (HSIC) introduction of Jarvis Analytics for Private Practices offers practice owners a simple, powerful tool to help improve practice success through data-driven decisions.
McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.
If You Invested $1000 in McKesson 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
SmileDirectClub (SDC) Q4 Earnings Lag Estimates, Margin Falls
by Zacks Equity Research
SmileDirectClub (SDC) reports lower-than-expected results for the fourth quarter, issues full-year 2022 sales guidance.
Here's Why You Should Invest In Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on continued growth in its consumer-centric digital solutions.
National Vision (EYE) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) performance in the fourth quarter of 2021.
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends and bullish fourth-quarter 2021 performance.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.
Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.